Otsuka (OTCMKTS:OTSKY) Downgraded by Zacks Research to “Strong Sell”

Otsuka (OTCMKTS:OTSKY) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday,Zacks.com reports.

Other analysts have also issued reports about the company. The Goldman Sachs Group lowered Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. UBS Group raised shares of Otsuka to a “hold” rating in a research note on Tuesday, January 27th. Finally, Morgan Stanley upgraded shares of Otsuka to an “overweight” rating in a research report on Friday, January 23rd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce”.

Otsuka Stock Down 3.0%

Shares of Otsuka stock opened at $31.85 on Monday. Otsuka has a twelve month low of $21.64 and a twelve month high of $34.93. The firm’s 50-day moving average price is $30.56 and its 200 day moving average price is $28.72.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.